Go back to trials list
Pilot Pragmatic Clinical Trial of Oral Iron Therapy in Children With Chronic Kidney Disease
Description
This is a pilot clinical trial of oral iron therapy in children with chronic kidney disease (CKD) and mild anemia. Eligible children will be randomized into a standard of care (iron sulfate) arm vs. no iron therapy arm for 3 months. The outcomes will include muscle strength, physical activity, and changes in eating behavior, which will be measured at enrollment and at the end of the study period.
Trial Eligibility
Key inclusion criteria: * Age 1-21 years old (muscle strength will be assessed only in children \>3 year old) * Estimated glomerular filtration rate (GFR) \< 90 ml/min/1.73m2 by bedside Schwartz formula \[height (cm) \*0.413 / serum creatinine (mg/dL)\] * Hemoglobin (Hb) more or equal than 9.0 at the previous clinic visit * Hb less than 11.5 g/dL in children younger than 5 years Hb less than 12.0 g/dL in children 5-12 years Hb \<12.5 g/dL in children 12-15 yrs and females \>15 yrs. Hb \<13.5 g/dL in males \>15 years (all at the previous clinic visit) Children with transferrin saturation ≤ 20% AND serum ferritin ≤ 100 ng/mL will be randomized into one of the arms Key exclusion criteria: * Transferrin saturation \<5% * Serum ferritin \< 10 ng/mL * Iron therapy or erythrocyte stimulating agents (erythropoietin) therapy within 3 months prior to randomization * Blood transfusion within 4 months prior to enrollment * Children on hemodialysis * Rapidly deteriorating kidney function or expectation for transplantation or dialysis in less than 3 months * Pregnancy and breast-feeding
Study Info
Organization
Weill Medical College of Cornell University
Primary Outcome
Change in muscle strength
Interventions
Locations Recruiting
Weill Cornell Medicine / New York Presbyterian Hospital
United States, New York, New York
Children's Hospital of Philadelphia
United States, Pennsylvania, Philadelphia
Interested in joining this trial?
Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.
Get the latest thought leadership on your Kidney Disease delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.